The OPAL study : A phase II study to evaluate the efficacy, safety, and tolerability of tosedostat (CHR-2797) in elderly subjects with treatment refractory or relapsed acute myeloid leukemia. 2010 ASCO Annual Meeting. Chicago

収録刊行物

• J Clin Oncol

  J Clin Oncol 0 2010